Skip to main
HOLX

Hologic (HOLX) Stock Forecast & Price Target

Hologic (HOLX) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 18%
Hold 64%
Sell 0%
Strong Sell 0%

Bulls say

Hologic is poised for strong financial performance, with expectations of 5-7% organic revenue growth driven by robust procedure volume growth and new product launches across its Diagnostics, Breast Health, and GYN Surgical segments. The company’s bull case scenario projects revenue growth accelerating to 7-9%, supported by improved operating margins and a robust balance sheet, which suggests a solid operational foundation for future expansion. Additionally, Hologic's strategies for margin enhancement, including potential tuck-in acquisitions and operational efficiencies, align well with projections of 8-12% earnings growth, positioning the company favorably for long-term success.

Bears say

Hologic's stock outlook remains negative due to anticipated revenue growth slowing to the low single digits (1-4%), primarily driven by weaknesses in the Diagnostics and Breast Health segments, which could lead to operating margins worse than expected and below-consensus earnings. The company's performance has been disappointing, with share prices down approximately 3.1% year-to-date and only modest increases of 9.4% and 4.4% over the last three and five years, respectively, suggesting persistent growth challenges. Risks such as a reduced demand for products amid a weakening global economy, integration difficulties from recent acquisitions, and increasing competition in key segments further exacerbate the company's growth and profitability outlook.

Hologic (HOLX) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 18% recommend Buy, 64% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hologic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hologic (HOLX) Forecast

Analysts have given Hologic (HOLX) a Hold based on their latest research and market trends.

According to 11 analysts, Hologic (HOLX) has a Hold consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hologic (HOLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.